Minimization of olaratumab drug waste using real-world data

Sheffield, Kristin M.; Beyrer, Julie; Watson, Ian; Stafford, Kathleen M.; Mills, Bradley J.; Ale-Ali, Amine

doi:10.2146/ajhp160254

Cited by 5 publications

(7 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Our estimation revealed that for therapy with specific cytotoxic and molecular targeted agents, which are expensive drugs used in large quantities, noticeable cost reductions would be expected. These results are consistent with the findings of other similar studies [ 4 , 5 , 10 , 11 ]. Further, some frequently used cytotoxic agents and molecular targeted agents might account for 70% of disposal costs [ 10 ].…”

Section: Discussionsupporting

confidence: 94%

“…Japan’s anticancer drug market exceeded US$10 billion in 2017, and this value is expected to increase to approximately US$13 billion in 2020 [ 1 ]. The significant increase in the use of expensive anticancer drugs has been accompanied by an increase in the amount of residual liquid discarded from drug preparations [ 2 – 5 ]. Under the Japanese insurance system, the final medical cost is calculated as the total amount of vial usage for each drug used for each patient.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Estimating the effect of optimizing anticancer drug vials on medical costs in Japan based on the data from a cancer hospital

Matsuo

Nomura

Uchiyama

et al. 2020

BMC Health Serv Res

View full text Add to dashboard Cite

Background The substantial increase in the use of expensive anticancer drugs has been accompanied by an increase in the amount of disposing residual liquid from drug preparations. Many Western countries, including the United States, have implemented drug vial optimization (DVO) to prevent the waste of anticancer drugs and have reported the reductions in the total drug costs. This study was designed to estimate the expected reduction in spending on anticancer drugs by Japanese cancer hospitals when DVO was implemented instead of individual preparations and to test the effectiveness of this approach. Methods We investigated the doses of drugs used and quantity specifications for individually prepared vials for patients who received anticancer drug treatment in December 2017 at the Outpatient Treatment Center of the National Cancer Center Hospital East. Based on these findings, we calculated the total quantity of each drug used on a given day, and the minimum cost for preparation of the number of specified combinations corresponding to the total cost (DVO preparation). Based on the differences in these two costs, we estimated the economic impact of implementing DVO. Results While the cost for anticancer drugs for the 1-month study period was US$3,305,595 (US$1 = \110) for individual preparations, the estimated cost for DVO preparations was US$3,092,955, equivalent to a reduction of US$212,640. Conclusions Based on these study results, implementation of DVO-based preparation of injectable anticancer drugs in Japan in 2017 would have resulted in saving approximately US$460 million. This calculation revealed the need for the Japanese government to modify the methods employed to calculate drug costs in the insurance system and develop policies for the proper and optimal use of medical resources.

show abstract

Section: Discussionsupporting

confidence: 94%

Section: Introductionmentioning

confidence: 99%

Estimating the effect of optimizing anticancer drug vials on medical costs in Japan based on the data from a cancer hospital

Matsuo

Nomura

Uchiyama

et al. 2020

BMC Health Serv Res

View full text Add to dashboard Cite

show abstract

“…21,22 Waste minimization of anticancer drugs would also require the selection of different appropriate dosages per drug, computer assistance in the management of leftover and the organization of patients with similar therapeutic protocols. 23,24 This would be possible through an internal policy of cost minimization. 19,[25][26][27] The illustration of the cost saved in comparison to the centralization impact helped to visualize the economic performance of the chemotherapy circuit and to make decisions in this direction.…”

Section: Discussionmentioning

confidence: 99%

Centralization impact and cost-saving study in a Moroccan hospital’s centralized unit of chemotherapy preparation

Adade

Benabbes

Belahcen³

et al. 2020

J Oncol Pharm Pract

View full text Add to dashboard Cite

Purpose The purpose of this study was to assess the cost saved and the amount of drug wasted when compounding anticancer drugs in the centralized unit for chemotherapy preparation. A secondary objective was to estimate the centralization impact of activities related to the preparation of chemotherapies. Methods This was a two-month, single-centre, prospective study conducted at the National Oncology Institute in Rabat. The cost saved and the amount of drug wasted were calculated using a standardized data collection sheet (the prescribed dose, the amount of drug deployed, the amount remaining after compounding, the amount of drug saved and the drug wastage). The centralization impact was calculated using the amount of drug wasted in the centralized unit for chemotherapy preparation and a theoretical amount of drug wasted without centralization of preparation. Results During the study period, the total amount of drug saved was 249,959.5 mg (7.2% of drug used), which represented 96,657 USD. The amount of drug wasted was 89,290.5 mg or 42275.5 USD. The drug waste per dilution and per drug was 6.4 mg [1.6-16.1]. While the potential savings over one year (580,000 USD) reached 13.9% of the cytostatic drugs budget for 2018, the potential drug waste cost reached 6.1%. The centralization impact is estimated at an average of 79.5% ± 13.7% waste reduction. Conclusion The outcome of our study showed that the grouping of prescriptions in centralized unit for chemotherapy preparation could result in significant savings on the amount of drugs deployed. The centralization of cytostatic preparations is of economic interest.

show abstract

“…These data points were selected based on a recent study surveying the median weight and BSA of 1175 patients with STS. 33 It clear that the drug cost associated with olaratumab and doxorubicin ($90 285) far exceed either doxorubicin monotherapy ($224) or AIM ($2445). However, AIM is generally administered as an inpatient infusion, thus incurring more direct medical costs.…”

Section: Financial Implicationsmentioning

confidence: 99%

Olaratumab: A Novel Platelet-Derived Growth Factor Receptor α-Inhibitor for Advanced Soft Tissue Sarcoma

Andrick

Gandhi

2017

Ann Pharmacother

View full text Add to dashboard Cite

show abstract

Minimization of olaratumab drug waste using real-world data

Abstract: Analysis of real-world patient weight and BSA data allowed olaratumab vial size optimization to enable maximal dosing flexibility with minimal drug waste.

Cited by 5 publications

References 17 publications

Estimating the effect of optimizing anticancer drug vials on medical costs in Japan based on the data from a cancer hospital

Estimating the effect of optimizing anticancer drug vials on medical costs in Japan based on the data from a cancer hospital

Centralization impact and cost-saving study in a Moroccan hospital’s centralized unit of chemotherapy preparation

Olaratumab: A Novel Platelet-Derived Growth Factor Receptor α-Inhibitor for Advanced Soft Tissue Sarcoma

Contact Info

Product

Resources

About